“Data just presented in an oral presentation at the ASCO GU conference demonstrated casdatifan’s potential to be the best-in-class HIF-2a inhibitor in what appears to be a two-horse rac ...
Casdatifan showed improvement in primary progressive disease rate (progressed at or before their first disease assessment), ORR and mPFS relative to published data from studies with HIF-2a ...
Hosted on MSN1mon
Gilead opts out of deal for Arcus cancer therapyCasdatifan is a small molecule designed to target the cancer-causing agent HIF-2a. Noting a recent data readout at a medical conference and possibly with Merck’s (MRK) Welireg in mind ...
What To Know: The financing is expected to support ongoing trials, including PEAK-1, a Phase 3 study for its HIF-2a inhibitor casdatifan in clear cell renal cell carcinoma (ccRCC). The stock ...
New data from ARC-20, a Phase 1/1b study of the HIF-2a inhibitor casdatifan in clear cell renal cell carcinoma (ccRCC), will be presented in a rapid oral session by Dr. Toni Choueiri, Dana-Farber ...
Hypoxia-inducible transcription factors, HIF-1a and HIF-2a, play a major role in these processes. These transcription factors bind to the same DNA response element and regulate mostly overlapping and ...
a HIF-2a inhibitor with best-in-class potential, in an oral plenary session by Dr. Toni K. Choueiri, Dana-Farber Cancer Institute, at the 2025 American Society of Clinical Oncology (ASCO ...
Casdatifan showed improvement in primary progressive disease rate (progressed at or before their first disease assessment), ORR and mPFS relative to published data from studies with HIF-2a inhibitors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback